Current understanding of the glial response to disorders of the aging CNS

doi:10.3389/fphar.2012.00095

. 2012 May 28:3:95.

doi: 10.3389/fphar.2012.00095. eCollection 2012.

Current understanding of the glial response to disorders of the aging CNS

Roger A Barker¹, Francesca Cicchetti

Affiliations

PMID: 22654755
PMCID: PMC3361074
DOI: 10.3389/fphar.2012.00095

Current understanding of the glial response to disorders of the aging CNS

Roger A Barker et al. Front Pharmacol. 2012.

. 2012 May 28:3:95.

doi: 10.3389/fphar.2012.00095. eCollection 2012.

Authors

Roger A Barker¹, Francesca Cicchetti

Affiliation

¹ Department of Clinical Neuroscience, Cambridge Centre for Brain Repair, University of Cambridge Cambridge, UK.

PMID: 22654755
PMCID: PMC3361074
DOI: 10.3389/fphar.2012.00095

Abstract

In this special issue of Frontiers in Pharmacology, we have asked leading experts to comment and review the evidence that inflammatory cells play a leading role in the pathological processes underlying neurodegenerative disorders. We now seek to draw these various observations together into a conclusion, with the hope that this will inform further work in this area and result in the identification of new therapeutic targets that will have a disease modifying effect.

Keywords: Alzheimer’s disease; Huntington’s disease; Parkinson’s disease; inflammation; microglia; motorneuron disease.

PubMed Disclaimer

Cited by

Corticostriatal network dysfunction in Huntington's disease: Deficits in neural processing, glutamate transport, and ascorbate release.
Rebec GV. Rebec GV. CNS Neurosci Ther. 2018 Apr;24(4):281-291. doi: 10.1111/cns.12828. Epub 2018 Feb 21. CNS Neurosci Ther. 2018. PMID: 29464896 Free PMC article. Review.
Neurodegenerative disorders: the Glia way forward.
Barker RA, Cicchetti F. Barker RA, et al. Front Pharmacol. 2014 Jul 15;5:157. doi: 10.3389/fphar.2014.00157. eCollection 2014. Front Pharmacol. 2014. PMID: 25076908 Free PMC article. No abstract available.
Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the HdhQ150/Q150 Mouse Model of Huntington's Disease.
Rattray I, Smith EJ, Crum WR, Walker TA, Gale R, Bates GP, Modo M. Rattray I, et al. PLoS One. 2017 Jan 18;12(1):e0168556. doi: 10.1371/journal.pone.0168556. eCollection 2017. PLoS One. 2017. PMID: 28099507 Free PMC article.

References

1. Banati R. B., Daniel S. E., Blunt S. B. (1998). Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson’s disease. Mov. Disord. 13, 221–22710.1002/mds.870130205 - DOI - PubMed
1. Bjorkqvist M., Wild E. J., Thiele J., Silvestroni A., Andre R., Lahiri N., Raibon E., Lee R. V., Benn C. L., Soulet D., Magnusson A., Woodman B., Landles C., Pouladi M. A., Hayden M. R., Khalili-Shirazi A., Lowdell M. W., Brundin P., Bates G. P., Leavitt B. R., Moller T., Tabrizi S. J. (2008). A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J. Exp. Med. 205, 1869–187710.1084/jem.20080178 - DOI - PMC - PubMed
1. Brownell A. L., Jenkins B. G., Isacson O. (1999). Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson’s disease. Biomed. Pharmacother. 53, 131–14010.1016/S0753-3322(99)80078-X - DOI - PubMed
1. Cicchetti F., Drouin-Ouellet J., Gross R. E. (2009a). Environmental toxins and Parkinson’s disease: what have we learned from pesticide-induced animal models? Trends Pharmacol. Sci. 30, 475–48310.1016/j.tips.2009.06.005 - DOI - PubMed
1. Cicchetti F., Saporta S., Hauser R. A., Parent M., Saint-Pierre M., Sanberg P. R., Li X. J., Parker J. R., Chu Y., Mufson E. J., Kordower J. H., Freeman T. B. (2009b). Neural transplants in patients with Huntington’s disease undergo disease-like neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 106, 12483–1248810.1073/pnas.0904239106 - DOI - PMC - PubMed

Grants and funding

LinkOut - more resources

Full Text Sources

[1] Banati R. B., Daniel S. E., Blunt S. B. (1998). Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson’s disease. Mov. Disord. 13, 221–22710.1002/mds.870130205 - DOI - PubMed

[2] Banati R. B., Daniel S. E., Blunt S. B. (1998). Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson’s disease. Mov. Disord. 13, 221–22710.1002/mds.870130205 - DOI - PubMed

[3] Bjorkqvist M., Wild E. J., Thiele J., Silvestroni A., Andre R., Lahiri N., Raibon E., Lee R. V., Benn C. L., Soulet D., Magnusson A., Woodman B., Landles C., Pouladi M. A., Hayden M. R., Khalili-Shirazi A., Lowdell M. W., Brundin P., Bates G. P., Leavitt B. R., Moller T., Tabrizi S. J. (2008). A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J. Exp. Med. 205, 1869–187710.1084/jem.20080178 - DOI - PMC - PubMed

[4] Bjorkqvist M., Wild E. J., Thiele J., Silvestroni A., Andre R., Lahiri N., Raibon E., Lee R. V., Benn C. L., Soulet D., Magnusson A., Woodman B., Landles C., Pouladi M. A., Hayden M. R., Khalili-Shirazi A., Lowdell M. W., Brundin P., Bates G. P., Leavitt B. R., Moller T., Tabrizi S. J. (2008). A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J. Exp. Med. 205, 1869–187710.1084/jem.20080178 - DOI - PMC - PubMed

[5] Brownell A. L., Jenkins B. G., Isacson O. (1999). Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson’s disease. Biomed. Pharmacother. 53, 131–14010.1016/S0753-3322(99)80078-X - DOI - PubMed

[6] Brownell A. L., Jenkins B. G., Isacson O. (1999). Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson’s disease. Biomed. Pharmacother. 53, 131–14010.1016/S0753-3322(99)80078-X - DOI - PubMed

[7] Cicchetti F., Drouin-Ouellet J., Gross R. E. (2009a). Environmental toxins and Parkinson’s disease: what have we learned from pesticide-induced animal models? Trends Pharmacol. Sci. 30, 475–48310.1016/j.tips.2009.06.005 - DOI - PubMed

[8] Cicchetti F., Drouin-Ouellet J., Gross R. E. (2009a). Environmental toxins and Parkinson’s disease: what have we learned from pesticide-induced animal models? Trends Pharmacol. Sci. 30, 475–48310.1016/j.tips.2009.06.005 - DOI - PubMed

[9] Cicchetti F., Saporta S., Hauser R. A., Parent M., Saint-Pierre M., Sanberg P. R., Li X. J., Parker J. R., Chu Y., Mufson E. J., Kordower J. H., Freeman T. B. (2009b). Neural transplants in patients with Huntington’s disease undergo disease-like neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 106, 12483–1248810.1073/pnas.0904239106 - DOI - PMC - PubMed

[10] Cicchetti F., Saporta S., Hauser R. A., Parent M., Saint-Pierre M., Sanberg P. R., Li X. J., Parker J. R., Chu Y., Mufson E. J., Kordower J. H., Freeman T. B. (2009b). Neural transplants in patients with Huntington’s disease undergo disease-like neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 106, 12483–1248810.1073/pnas.0904239106 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Current understanding of the glial response to disorders of the aging CNS

Affiliation

Current understanding of the glial response to disorders of the aging CNS

Authors

Affiliation

Abstract

Similar articles

Cited by

References

Grants and funding

LinkOut - more resources

Full Text Sources

Abstract

Similar articles

Cited by

References

Related information

Grants and funding

LinkOut - more resources

Full Text Sources